Immunotherapy is the only treatment for allergy that has the potential to alter the natural course of the disease. Sublingual immunotherapy (SLIT) for grass pollen-induced rhino-conjunctivitis has been developed to make immunotherapy available to a broader group of allergic patients. In the largest clinical programme ever conducted with allergen-specifi c immunotherapy, over 1,700 adults and 260 children have been exposed to Grazax ® . Grazax is formulated as an oral lyophilisate (tablet) for sublingual administration, containing 75,000 SQ-T standardized allergen extract of grass pollen from Phleum pratense. Grazax is indicated for treatment of grass pollen-induced rhinitis and conjunctivitis in adult patients with clinically relevant symptoms and diagnosed with a positive skin prick test and/or specifi c IgE test to grass pollen. In phase I trials doses from 2,500 to 1,000,000 SQ-T were tested. All doses were well tolerated and 75,000 SQ-T, with approximately 15 μg major allergen protein, was chosen as the optimal dose. Three phase III trials are ongoing, one being a long-term trial. Results from GT-08 trial fi rst and second treatment years showed a reduction of 30% and 36%, respectively, in daily rhino-conjunctivitis symptom scores and a reduction of 38% and 46% of daily rhinoconjunctivitis medication scores compared with placebo over the entire grass pollen season. Subjects treated with Grazax also had an increased number of well days and improved quality of life, and more subjects experienced excellent rhino-conjunctivitis control. The most common adverse events related to Grazax are local reactions, such as pruritus, edema mouth, ear pruritus, throat irritation, and sneezing. We conclude that Grazax is effi cacious and safe for treatment of rhino-conjunctivitis due to grass pollen allergy.
Introduction
Overall, it is estimated that one quarter of the European population suffers from respiratory allergies such as allergic rhinitis, and the prevalence is increasing, although it varies among countries (Linneberg et al 2000; Dahl et al 2004) . Grass pollen is the most common cause of respiratory allergies, and is associated with more than 50% of allergic rhinitis cases (Bauchau and Durham 2004) . Allergic rhinitis can leave a significant burden of residual symptoms even among those receiving optimal symptomatic treatment (White et al 1998) . Only allergen-specifi c immunotherapy (SIT) targets the underlying allergic disease, having the potential to produce long-term remission and to prevent the development of new sensitizations and asthma. SIT increases the tolerability to a specifi c allergen, thereby reducing the allergic symptoms and the consumption of symptomatic treatment.
Grazax ® (ALK-Abello A/S, Hoersholm, Denmark) is the fi rst registered and marketed allergy tablet (oral lyophilisate) to treat the underlying cause of grass pollen-induced rhinoconjunctivitis in adult subjects. In order to ensure treatment of subjects with the correct indication, Grazax should be prescribed only by doctors with special knowledge and experience in treating allergic diseases. Grazax is a home-based treatment and requires fewer visits to the doctor compared with traditional subcutaneous SIT. Visits are greatly reduced from 39 with subcutaneous SIT to about 6 visits with Grazax, contributing to a more cost-effective treatment compared with subcutaneous treatment under the conviction that the treatment is as effective.
Doses and substance
The recommended daily dose for adults is one tablet/ oral lyophilisate (75,000 SQ-T/2,800 BAU), containing approximately 15 μg major allergen Phleum pratense (Calderon et al 2007) . Subjects should start treatment as a minimum 2 months prior to the grass pollen season without any up-dosing period (Calderon et al 2005) . Grazax contains the same active pharmaceutical ingredient (API) as Alutard SQ ® grass pollen, which has been used for more than 20 years as a subcutaneous SIT. The API is a standardized allergen extract from Phleum pratense grass pollen. It has been shown to have extensive cross-reactivity of allergenic components of grass pollens from different species (Andersson and Lidholm 2003; Weber 2005) .
Pharmacokinetics
As the active molecules of the allergens in Grazax are polypeptides and proteins, it is expected that these are hydrolyzed to amino acids and small polypeptides in the lumen of the gastrointestinal tract and in the local tissues. There is no evidence to suggest that the allergens present in Grazax are absorbed into the vascular system to any signifi cant extent (Senel et al 2001; Bagnasco et al 2003 Bagnasco et al , 2005 Moingeon et al 2006) . Consequently, no pharmacokinetics trials have been conducted.
Mechanism of actionpharmacodynamics in humans
The mechanism of SIT is very complex and the exact mechanism of action is still not fully understood. However, it is widely acknowledged that subcutaneous and sublingual SIT acts as a modifi er of the immune system. The mechanism is a combination of altered regulation of IgE syntheses and induction of IgE-blocking antibodies, with the capacity to competitively inhibit the interaction between allergen and IgE. Further effects include a shift from Th2 to regulatory T-cells and inhibition of facilitating antigen presentation of the specifi c T-cells. For Grazax it is documented that the amount of antibodies in serum is dependent on doses, and Grazax and Alutard SQ Phleum pratense give a clear and qualitatively similar antibody response (Malling et al 2006) .
Clinical trials
The clinical development program for Grazax was initiated to investigate the optimal dosing regimen as well as the tolerability, safety, and effi cacy profi le of Grazax.
Five phase I trials (GT-01, GT-03, GT-04, GT-09 and GT-11) assessed the tolerability. Doses from 2,500 to 1,000,000 SQ-T were tested in subjects with grass pollen allergy without any up-dosing period for any of the doses. The highest dose tested was 13 times higher than the approved dose (75,000 SQ-T). Even the high doses of Grazax were well tolerated, primarily with local adverse events, and no serious or systemic adverse events were reported (Kleine-Tebbe et al 2006). Furthermore, clinical safety and effi cacy were investigated in a phase II/III trial (GT-02), one phase II trial (GT-07) and one phase III effi cacy trial (GT-08). Long-term effi cacy and safety were investigated in an extension of the GT-08 trial, and interim results after 1 and 2 years have been published (Dahl et al 2006a (Dahl et al , 2008 . The effect of a compliance device on treatment compliance was investigated in a phase IIIb trial (GT-10 trial). Three phase III trials are ongoing, though the trial periods for GT-12 and GT-14 are completed.
The number of subjects exposed to Grazax in the completed clinical trials is 1,619; in addition 860 adults are exposed in the on-going GT-08 extension and GT-14 study. A number of subjects are also exposed in relation to ongoing phase IV activities. The patient exposure on the market is, as of December 2007, 6,936 treatment years. Table 1 shows an overview of the completed and ongoing trials on Grazax.
Based on results from the fi rst year of GT-08, Grazax was approved in 27 European countries for treatment of grass pollen-induced rhinitis and conjunctivitis in adults with clinically relevant symptoms and diagnosed with a positive skin prick test and/or specifi c IgE test to grass pollen.
In GT-08, trial treatment was initiated at least 16 weeks before the anticipated start of the grass pollen season, and the effi cacy was measured according to the newest recommendation from the World Allergy Organisation (Canonica et al 2007) . Six allergic symptoms were rated daily (runny nose, blocked nose, sneezing, itchy nose, gritty feeling/red/itchy eyes, and watery eyes). Subjects treated with Grazax had a numerically lower symptom score than the placebo group. This was evident in both nose and eye symptoms during the entire grass pollen season. During the fi rst and second treatment years Grazax reduced mean daily rhino-conjunctivitis symptom score by 30% and 36%, respectively (Figure 1) , and mean daily rhino-conjunctivitis medication score by 38% and 46%, respectively, compared with placebo over the entire grass pollen season (Figure 2 ). The differences in symptom and medication score differed signifi cantly (p Ͻ 0.0001) from the placebo group. These results confi rmed results obtained from earlier trials with Grazax (Durham et al 2006; Dahl et al 2006b) , and are consistent with the effi cacy results reported for subcutaneous SIT (Frew et al 2006) . Subjects in the Grazax group also reported an increased number of well days during the grass pollen season (days with few symptoms and no need for rescue medication), improved quality of life (assessed by Juniper's Rhino-conjunctivitis Quality of Life Questionnaire) (Junier and Guyatt 1991), and more subjects experienced excellent rhino-conjunctivitis control compared with the placebo group (Durham et al 2007; Rak et al 2007) . These results support the contention that reductions in rhino-conjunctivitis medication and symptoms score translate into important benefi ts for the subjects and therefore can be considered clinically relevant.
In addition, 82% and 69% of the subjects treated with Grazax felt much better or better compared with previous grass pollen season during the fi rst and second year. For comparison 54% of the subjects (fi rst grass pollen season) and 57% of subjects (second grass pollen season) in the placebo group felt much better or better compared with previous grass pollen season. The high placebo effect can partly be explained by the fact that the placebo group used more medication than the Grazax group (Dahl et al 2006a) .
Safety
Even though the reported effi cacy of subcutaneous and sublingual immunotherapy is of similar magnitude, the treatment regimen and the safety profi les are completely different. The expected adverse events (AE) during subcutaneous immunotherapy are largely of two types, local reactions at the injections site and systemic reactions characterized by generalized signs and/or symptoms occurring distant from the injection site. Since the injection of allergens against which a subject has IgE antibodies may induce anaphylactic shock, it is recommended that all subjects are observed for 20 or 30 minutes after each injection and the treatment should be performed only by specialists (Bousquet et al 1998) . In contrast Grazax treatment is primarily characterized by frequent but local reactions, located in the mouth and throat, which mostly were mild to moderate. In the majority of the subjects these reactions started early in therapy, lasted from minutes to hours after each intake of Grazax, and tended to subside spontaneously within 1 to 7 days. The most common reported AE were oral pruritus, edema mouth, ear pruritus, throat irritation, and sneezing. Less commonly reported AE were headache, oral paraesthesia, eye pruritus, conjunctivitis, cough, asthma, pharyngitis, rhinorrhoea, nasal congestion, rhinitis throat tightness, pruritus, and fatigue. As a precautionary action the fi rst tablet is administered in the clinic under medical supervison. Grazax is contraindicated in the case of hypersensitivity to any of the excipients in the oral lyophilisate (tablet); in the case of malignancy or systemic diseases affecting the immune system; in case of infl ammatory conditions in the oral cavity with severe symptoms such as oral lichen planus with ulcerations or severe oral mycosis; and in patients with uncontrolled or severe asthma (FEV 1 Ͻ 70% of predicted value after adequate pharmacologic treatment).
Trials in the pediatric population have also been performed (Ibanez et al 2007) . Grazax was well tolerated in children, and further clinical investigations of the effi cacy and safety in children have shown corresponding effects to the results from the trials in adults which led to the European marketing approval in 2006. Grazax has been demonstrated to be effi cacious and well tolerated as home treatment and this treatment concept might allow immunotherapy treatment for a broader population including subjects not having easy access to specialists in immunotherapy and subjects who have been reluctant to undergo injection immunotherapy.
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